The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis
Background Sepsis and septic shock are formidable and complications in surgery with mortality 20–50%. In the pathogenesis of sepsis, a significant role belongs to bacterial endotoxin (LPS - liposaccharide).Aim of study Assessment of the efficacy of selective lipopolysaccharides hemosorption (SLH) in...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Sklifosovsky Research Institute for Emergency Medicine, Public Healthcare Institution of Moscow Healthcare Department
2020-10-01
|
| Series: | Неотложная медицинская помощь |
| Subjects: | |
| Online Access: | https://www.jnmp.ru/jour/article/view/929 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839580053939159040 |
|---|---|
| author | G. V. Bulava S. I. Rey G. A. Berdnikov O. V. Nikitina A. K. Shabanov N. V. Borovkova N. N. Salina M. A. Godkov |
| author_facet | G. V. Bulava S. I. Rey G. A. Berdnikov O. V. Nikitina A. K. Shabanov N. V. Borovkova N. N. Salina M. A. Godkov |
| author_sort | G. V. Bulava |
| collection | DOAJ |
| description | Background Sepsis and septic shock are formidable and complications in surgery with mortality 20–50%. In the pathogenesis of sepsis, a significant role belongs to bacterial endotoxin (LPS - liposaccharide).Aim of study Assessment of the efficacy of selective lipopolysaccharides hemosorption (SLH) in treatment of sepsis.Material and methods We examined 65 patients with developed sepsis or suspected presence of gram-negative infection. Patients were retrospectively divided into two groups. In Group 1, 27 patients received Polymyxin B hemoperfusion using Toraymyxin cartridges. In Group 2 (38 patients), adsorber Alteco (LPSA) was used.Results It was established that 28-day mortality was 11.1% in Polymyxin group and 28.9% in LPS group A, p = 0.091, 60-day mortality was 33.3 and 55.3%, respectively (p=0.065). The use of SLH contributed to a decrease in the activity of endotoxin (EAA) from 0.52 (0.39; 0.65) to 0.40 (0.36; 0.57) EU (p=0.330) in Polymyxin group and from 0.59 ( 0.42; 0.72) to 0.54 (0.40; 0.81) EU ( p = 0.981) in the LPS-A group. At the same time, the level of procalcitonin (PCT) in the blood statistically significantly decreased from 8.4 (3.6; 29.0) to 4.8 (1.9; 36.3) ng/ml (p=0.0117) only in the LPS-A group. The level of C-reactive protein (CRB) in the blood statistically significantly decreased only in the Polymyxin group, from 205 (154; 264) to 162 (106; 202) mg/L (p<0.001). After SPH procedures, there was a tendency to a decrease in the level of blood cytokines in both groups. Conclusion 1. The trend of better survival among patients was noted during hemoperfusion when using Polymyxin B in comparison with the results of adsorption of lipopolysaccharide with Alteco cartridges: so, 28-day mortality was 11.1 and 28.9%, respectively (statistically not significant).2. As a result, the procedure of selective lipopolysaccharides hemosorbtion on hemosorbents with Polymyxin B in blood significantly decreased level of C-reactive protein (21%), there was statistically insignificant decrease in the level of endotoxin activity (23.1%), lipopolysaccharide binding protein (21.6%), procalcitonin (2.4 times), presepsin (20%), as well as the level of interleukin-6 (3.4 times) and interleukin-10 (1.6 times) . Adsorption of lipopolysaccharide with Alteco cartridges leads to a statistically significant reduction of procalcitonin in blood (1.8 times), and statistically insignificant decrease of: endotoxin activity (9.3%), lipopolysaccharide binding protein (28.6%), interleukin-6 (3.8 times), interleukin-10 (7.1 times) and soluble receptor to interleukin-2 (2.2 times). |
| format | Article |
| id | doaj-art-18bcc13b9e85420e9a9fdbab8e4a8a4c |
| institution | Matheson Library |
| issn | 2223-9022 2541-8017 |
| language | Russian |
| publishDate | 2020-10-01 |
| publisher | Sklifosovsky Research Institute for Emergency Medicine, Public Healthcare Institution of Moscow Healthcare Department |
| record_format | Article |
| series | Неотложная медицинская помощь |
| spelling | doaj-art-18bcc13b9e85420e9a9fdbab8e4a8a4c2025-08-04T10:30:22ZrusSklifosovsky Research Institute for Emergency Medicine, Public Healthcare Institution of Moscow Healthcare DepartmentНеотложная медицинская помощь2223-90222541-80172020-10-019220120910.23934/2223-9022-2020-9-2-201-209596The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of SepsisG. V. Bulava0S. I. Rey1G. A. Berdnikov2O. V. Nikitina3A. K. Shabanov4N. V. Borovkova5N. N. Salina6M. A. Godkov7N.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare DepartmentBackground Sepsis and septic shock are formidable and complications in surgery with mortality 20–50%. In the pathogenesis of sepsis, a significant role belongs to bacterial endotoxin (LPS - liposaccharide).Aim of study Assessment of the efficacy of selective lipopolysaccharides hemosorption (SLH) in treatment of sepsis.Material and methods We examined 65 patients with developed sepsis or suspected presence of gram-negative infection. Patients were retrospectively divided into two groups. In Group 1, 27 patients received Polymyxin B hemoperfusion using Toraymyxin cartridges. In Group 2 (38 patients), adsorber Alteco (LPSA) was used.Results It was established that 28-day mortality was 11.1% in Polymyxin group and 28.9% in LPS group A, p = 0.091, 60-day mortality was 33.3 and 55.3%, respectively (p=0.065). The use of SLH contributed to a decrease in the activity of endotoxin (EAA) from 0.52 (0.39; 0.65) to 0.40 (0.36; 0.57) EU (p=0.330) in Polymyxin group and from 0.59 ( 0.42; 0.72) to 0.54 (0.40; 0.81) EU ( p = 0.981) in the LPS-A group. At the same time, the level of procalcitonin (PCT) in the blood statistically significantly decreased from 8.4 (3.6; 29.0) to 4.8 (1.9; 36.3) ng/ml (p=0.0117) only in the LPS-A group. The level of C-reactive protein (CRB) in the blood statistically significantly decreased only in the Polymyxin group, from 205 (154; 264) to 162 (106; 202) mg/L (p<0.001). After SPH procedures, there was a tendency to a decrease in the level of blood cytokines in both groups. Conclusion 1. The trend of better survival among patients was noted during hemoperfusion when using Polymyxin B in comparison with the results of adsorption of lipopolysaccharide with Alteco cartridges: so, 28-day mortality was 11.1 and 28.9%, respectively (statistically not significant).2. As a result, the procedure of selective lipopolysaccharides hemosorbtion on hemosorbents with Polymyxin B in blood significantly decreased level of C-reactive protein (21%), there was statistically insignificant decrease in the level of endotoxin activity (23.1%), lipopolysaccharide binding protein (21.6%), procalcitonin (2.4 times), presepsin (20%), as well as the level of interleukin-6 (3.4 times) and interleukin-10 (1.6 times) . Adsorption of lipopolysaccharide with Alteco cartridges leads to a statistically significant reduction of procalcitonin in blood (1.8 times), and statistically insignificant decrease of: endotoxin activity (9.3%), lipopolysaccharide binding protein (28.6%), interleukin-6 (3.8 times), interleukin-10 (7.1 times) and soluble receptor to interleukin-2 (2.2 times).https://www.jnmp.ru/jour/article/view/929sepsisseptic shockendotoxin lipopolysaccharide selective hemosorbtionpolymyxin b hemoperfusionlps adsorber altecoextracorporeal hemocorrection |
| spellingShingle | G. V. Bulava S. I. Rey G. A. Berdnikov O. V. Nikitina A. K. Shabanov N. V. Borovkova N. N. Salina M. A. Godkov The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis Неотложная медицинская помощь sepsis septic shock endotoxin lipopolysaccharide selective hemosorbtion polymyxin b hemoperfusion lps adsorber alteco extracorporeal hemocorrection |
| title | The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis |
| title_full | The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis |
| title_fullStr | The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis |
| title_full_unstemmed | The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis |
| title_short | The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis |
| title_sort | use of selective hemosorption of lipopolysaccharides in the complex treatment of sepsis |
| topic | sepsis septic shock endotoxin lipopolysaccharide selective hemosorbtion polymyxin b hemoperfusion lps adsorber alteco extracorporeal hemocorrection |
| url | https://www.jnmp.ru/jour/article/view/929 |
| work_keys_str_mv | AT gvbulava theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT sirey theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT gaberdnikov theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT ovnikitina theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT akshabanov theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT nvborovkova theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT nnsalina theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT magodkov theuseofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT gvbulava useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT sirey useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT gaberdnikov useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT ovnikitina useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT akshabanov useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT nvborovkova useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT nnsalina useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis AT magodkov useofselectivehemosorptionoflipopolysaccharidesinthecomplextreatmentofsepsis |